Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2838330 | 0.70 | MAOB (0.39) | MAOBCA1CA2ARG2 | |
| SCHEMBL1306041 | 0.69 | MAOB (0.57) | MAOBCA1CA2ARG2CALM1 | |
| SCHEMBL7943367 | 0.69 | MAOB (0.50) | MAOBCA1CA2ARG2CALM1 | |
| SCHEMBL1073371 | 0.61 | CES1 (0.39) | CALM1MEN1KMT2ATDP1 | |
| SCHEMBL27944851 | 0.61 | MAOB (0.52) | MAOBCA1CA2ARG2CALM1 | |
| SCHEMBL1524697 | 0.61 | MAOB (1.00) | MAOBCA1CA2ARG2CALM1 | |
| SCHEMBL155055 | 0.61 | MAOB (1.00) | MAOBCA1CA2ARG2CALM1 | |
| SCHEMBL155054 | 0.61 | MAOB (1.00) | MAOBCA1CA2ARG2CALM1 | |
| SCHEMBL74275 | 0.61 | MAOB (0.67) | MAOBCA1CA2ARG2CALM1 | |
| Phenylacetaldehyde SCHEMBL28046815 | 0.60 | MAOB (0.57) | MAOBCA1CA2ARG2CALM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785574-B2 | Bridged metallocene compound, olefin polymerization catalyst containing the same, and ethylene polymer obtained with the catalyst | MITSUI CHEMICALS, INC. (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20140114031-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST | PRIME POLYMER CO., LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| EP-2218725-B1 | BRIDGED METALLOCENE OLEFIN POLYMERIZATION CATALYST AND ETHYLENE POLYMER OBTAINED BY USING THE CATALYST | MITSUI CHEMICALS INC (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-20100292421-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST | MITSUI CHEMICALS, INC. | 2010-11-18 | — | — | US | disclosed |
| EP-2218725-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST USING THE COMPOUND AND ETHYLENE POLYMER OBTAINED BY USING THE CATALYST | Mitsui Chemicals, Inc. (JP) | 2010-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292421-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST | CAD, ENDOD1, CCT7 | MAOB 2686/4885CA1 2956/4885CA2 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.